Time interval from transurethral resection of bladder tumor to onset of BCG induction does not impact therapeutic response
Patrick J. Hensley(University of Kentucky), A. M. Kamat(The University of Texas MD Anderson Cancer Center), R. Li, Justin T. Matulay(Levine Cancer Institute), Nathan A. Brooks(Eli Lilly (United States)), Kelly K. Bree(The University of Texas MD Anderson Cancer Center), G. Nogueras Gonzalez(Moffitt Cancer Center), Neema Navai(The University of Texas MD Anderson Cancer Center), H. Grossman, Colin P. Dinney(The University of Texas MD Anderson Cancer Center)
Cited by 0
Related Papers
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial
|The Lancet Oncology|2020|459
Multicenter Assessment of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer
|European Urology|2014|297
Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder Cancer
|The Journal of Urology|2019|190